SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-009006
Filing Date
2024-03-05
Accepted
2024-03-05 17:10:30
Documents
16
Period of Report
2024-03-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20240305.htm   iXBRL 8-K 27940
2 EX-99.1 a2023q4ex991earningsrelease.htm EX-99.1 273893
6 GRAPHIC image_0.jpg GRAPHIC 24016
  Complete submission text file 0001628280-24-009006.txt   487486

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20240305.xsd EX-101.SCH 2013
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20240305_lab.xml EX-101.LAB 24139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20240305_pre.xml EX-101.PRE 12611
17 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20240305_htm.xml XML 2723
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 24722166
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)